Consult
Log In
Menu
Consult
Log in

by PierianDx, on August 29, 2018

Are you considering offering clinical NGS testing or looking for an economical approach to building your program? 

Read Story
Topics:Blog

by PierianDx, on August 24, 2018

We Know Precision Medicine is a series of blog posts and articles about the people of PierianDx and how we know precision medicine through our expertise and personal experiences. In this article, Shalini Verma, Laboratory and Medical Director, discusses her role at PierianDx and how our products and services will help make precision medicine a routine component of healthcare.  

Read Story
Topics:Blog

by PierianDx, on August 14, 2018

Recently we hosted a webinar in which Medical Director, Shalini Verma, and VP Product, Andy Bredemeyer, reviewed and applied the Association for Molecular Pathology (AMP) joint consensus guidelines for the interpretation and reporting of sequence variants in cancer. 

Read Story
Topics:Blog

by Lisa Owen, on July 26, 2018

"We Know Precision Medicine" is a series of blog posts and articles about the people of PierianDx and how we know precision medicine through our expertise and personal experiences. In this article, Andy Bredemeyer, VP Product, discusses how PierianDx has given him the opportunity to impact patient care in a way he never thought possible. 

Read Story
Topics:Blog

by Lisa Owen, on July 13, 2018

Preparing for our upcoming webinar -- A Practice-based Guide for Interpretation and Reporting of Sequence Variants in Cancer--caused us to think about the evolution of next generation sequencing (NGS) into the clinic and how there’s hasn't been a dull moment since this technology was first introduced.

Read Story
Topics:Blog

by PierianDx, on June 27, 2018

"We Know Precision Medicine" is a series of blog posts and articles about the people of PierianDx and how we know precision medicine through our expertise and personal experiences. In this first article, Rakesh Nagarajan, Founder and Executive Chairman, discusses the origin of PierianDx and why he has devoted his life to make precision medicine a reality.

Read Story
Topics:Blog

by Josh Forsythe, on June 11, 2018

PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that the Department of Anatomical Pathology PathWest Laboratory Medicine will use the company’s Clinical Genomics WorkSpace™ (CGW) platform, the industry’s leading integrated workspace for clinical genomic analytics, classification, interpretation and reporting.

Read Story
Topics:News

by Josh Forsythe, on June 1, 2018

Topics:News

by Josh Forsythe, on May 23, 2018

MAY 24, 2018 -- ST. LOUIS -- PierianDx, the leader in clinical genomics solutions, announced today that it has appointed Michael L. Sanderson as Chief Executive Officer and Director of the Board. In his new role, Sanderson will execute on the company’s strategy to integrate PierianDx’s unique value proposition for molecular labs into the broader precision medicine and healthcare delivery markets.

Read Story
Topics:News

by Josh Forsythe, on May 13, 2018

MAY 14, 2018 -- ST. LOUIS -- PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that it has executed a distribution agreement with ScienceVision, a leading provider of end-to-end genomic solutions in the Asia Pacific region.

Read Story
Topics:News

by PierianDx, on April 19, 2018

In the U.S. alone, there are nearly 700,000 people living with a primary brain tumor. And each year, there are nearly 70,000 new diagnoses and 17,000 deaths. [1]  With over 120 different types of tumors and a tricky blood-brain barrier to permeate, brain tumors are notoriously difficult to treat, and the standard of care hasn’t changed in many years. More than any other type of cancer, brain tumor survivors face motor, cognitive, and psychological challenges.

Read Story
Topics:Blog

by Josh Forsythe, on April 17, 2018

PierianDx, the leading genomics technology companythat enables precision medicine,announced today a strategic partnership with RTI International to help solve the problem of translating complex genomic data into actionable clinical insight to advance precision medicine.  The partnership includes investment and collaboration on product, service and market expansion.

Read Story
Topics:News